Zobrazit v EDS

15 years supporting adherence to oral anti-cancer treatment: use of the MASCC Oral Agent Teaching Tool (MOATT) worldwide, a review for the future

Uloženo v:
Podrobná bibliografie
Název: 15 years supporting adherence to oral anti-cancer treatment: use of the MASCC Oral Agent Teaching Tool (MOATT) worldwide, a review for the future
Autoři: Sultan Kav, Mapi Fleury, Paz Fernández-Ortega, Ellen F. Manzullo, Kimberley-Ann Kerr, Regina DeGennaro, Pamela K. Ginex
Zdroj: Support Care Cancer
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Dipòsit Digital de la UB
instname
Supportive care in cancer, vol. 33, no. 3, pp. 229
Informace o vydavateli: Springer Science and Business Media LLC, 2025.
Rok vydání: 2025
Témata: Educació dels pacients, Therapeutic use, Administration, Oral, Antineoplastic Agents, Patient education, Review, Medicaments antineoplàstics, Medication Adherence, Patient Education as Topic, Ús terapèutic, Neoplasms, Antineoplastic agents, Humans, Antineoplastic Agents/administration & dosage, Antineoplastic Agents/therapeutic use, Patient Education as Topic/methods, Neoplasms/drug therapy, Implementation, MASCC oral agent teaching tool, MOATT, Therapeutic adherence
Popis: Introduction The MASCC Oral Agent Teaching Tool (MOATT®) was developed to address the challenges of patient education and adherence in the context of oral anticancer agents. Despite its evidence-based design and global availability, there is limited documentation on its application in clinical practice and research. This review aims to assess the extent of MOATT usage and evaluate the impact on patient outcomes. Methods A scoping review was conducted following Joanna Briggs Institute and PRISMA-ScR reporting standards. Databases included CINAHL, Embase, PsycInfo, Web of Science, and PubMed. Inclusion criteria were studies published between 2010 and 2023 that used MOATT in clinical practice or research. Two reviewers independently screened and extracted data, with discrepancies resolved by consensus. Findings Seventeen studies met the inclusion criteria, from nine countries. The MOATT was most used by nurses and pharmacists to guide patient education when initiating new oral anticancer therapies. Reported outcomes included improved patient knowledge, understanding of medication regimens, and comfort in managing treatments. However, only six studies assessed medication adherence, with mixed results. The tool was adapted in various settings, yet there was a notable lack of detailed reports on its usage and outcomes, highlighting underutilization and potential barriers to broader implementation. Conclusion The MOATT is a valuable tool for supporting patients on oral anticancer agents yet is underutilized in practice. Future research should focus on understanding the barriers to its adoption, exploring patient and provider perspectives, and integrating implementation science to enhance its use in diverse clinical contexts.
Druh dokumentu: Article
Other literature type
Popis souboru: application/pdf
Jazyk: English
ISSN: 1433-7339
0941-4355
DOI: 10.1007/s00520-025-09274-3
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/40014143
https://hdl.handle.net/2445/221371
https://serval.unil.ch/resource/serval:BIB_EC444C2E4C83.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_EC444C2E4C839
https://serval.unil.ch/notice/serval:BIB_EC444C2E4C83
Rights: CC BY
Přístupové číslo: edsair.doi.dedup.....3baf987684d259cae02c2c8110eead65
Databáze: OpenAIRE
Popis
Abstrakt:Introduction The MASCC Oral Agent Teaching Tool (MOATT®) was developed to address the challenges of patient education and adherence in the context of oral anticancer agents. Despite its evidence-based design and global availability, there is limited documentation on its application in clinical practice and research. This review aims to assess the extent of MOATT usage and evaluate the impact on patient outcomes. Methods A scoping review was conducted following Joanna Briggs Institute and PRISMA-ScR reporting standards. Databases included CINAHL, Embase, PsycInfo, Web of Science, and PubMed. Inclusion criteria were studies published between 2010 and 2023 that used MOATT in clinical practice or research. Two reviewers independently screened and extracted data, with discrepancies resolved by consensus. Findings Seventeen studies met the inclusion criteria, from nine countries. The MOATT was most used by nurses and pharmacists to guide patient education when initiating new oral anticancer therapies. Reported outcomes included improved patient knowledge, understanding of medication regimens, and comfort in managing treatments. However, only six studies assessed medication adherence, with mixed results. The tool was adapted in various settings, yet there was a notable lack of detailed reports on its usage and outcomes, highlighting underutilization and potential barriers to broader implementation. Conclusion The MOATT is a valuable tool for supporting patients on oral anticancer agents yet is underutilized in practice. Future research should focus on understanding the barriers to its adoption, exploring patient and provider perspectives, and integrating implementation science to enhance its use in diverse clinical contexts.
ISSN:14337339
09414355
DOI:10.1007/s00520-025-09274-3